Cancer News and Research

Latest Cancer News and Research

Oncothyreon proposes underwritten public offering of common stock

Oncothyreon Inc. today announced its intention to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering.

29 Mar 2012

Vaccination for HPV reduces risk of renewed disease

The vaccination against human papillomavirus (HPV) reduces the risk of a renewed HPV-associated illness in patients who have already had diseases as a consequence of an HPV infection.

29 Mar 2012

OncoSec Medical closes sale of 31,000,000 shares of common stock in registered public offering

OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, announced today the closing of the sale to institutional investors of an aggregate of 31,000,000 shares of its common stock at $0.25 per share in a registered public offering.

29 Mar 2012

New technique could restore fertility of boys undergoing cancer treatment

Treatments for childhood cancers are increasingly successful with cure rates approaching 80%, but success often comes with a downside for the surviving men: the cancer treatments they received as boys can leave them sterile as adults. Now, a research team led by Ralph Brinster of the University of Pennsylvania School of Veterinary Medicine has completed a 14-year experiment that gives hope for a technique that could restore their fertility.

29 Mar 2012

Obstacles standing in the way of cancer prevention

More than half of all cancer is preventable, and society has the knowledge to act on this information today, according to Washington University public health researchers at the Siteman Cancer Center in St. Louis.

29 Mar 2012

Study calls for re-examination of criteria used to prioritize liver transplant candidates

Patients with end-stage liver disease complicated by the most common type of liver cancer - hepatocellular carcinoma (HCC) - are less likely to die or become too sick for a transplant while waiting for a new liver than those with other complications of end-stage liver disease, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

29 Mar 2012

Change in registry protocols leads to underreporting of myeloid malignancies

Researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues from the UF Shands Cancer Center in Gainesville, Fla., have found that cases of myeloid malignancies are being underreported since a change in registry protocols and laboratory practices starting in 2001.

29 Mar 2012

Sun damage revealed by UV photographs show skin cancer risk

Look at a middle school assembly - during their lifetime one in 50 of these kids will develop melanoma, the most serious form of skin cancer that kills 48,000 people every year, worldwide. Now look at these kids again - which are at highest risk? You can't tell, but a study recently published in the Journal of the American Academy of Dermatology shows that UV photography might provide important information about risk, not visible to the naked eye.

29 Mar 2012

Increasing incidences of brain tumours calls for more spend on vital research

With more children and people under the age of 40 dying of a brain tumour than any other cancer in the United Kingdom, a leading researcher at Queen's University Belfast is calling for an increase in spending on vital research.

29 Mar 2012

Broad Institute, Novartis develop cancer cell line encyclopedia

Novartis and the Broad Institute have developed a cancer cell line encyclopedia that catalogues the genetic and molecular profiles of almost 1,000 human cancer cell lines used in drug research and development. Results of the collaboration, published in the journal Nature and released in advance online today, may allow scientists around the world to use this information to improve cancer clinical trial design and further cancer research.

29 Mar 2012

Roche announces increase in offer price for outstanding Illumina shares

Roche announced today that it has increased its offer price for all outstanding publicly-held shares of Illumina, Inc. to US$ 51.00 per share in cash.

From Illumina, Inc. 29 Mar 2012

Navidea announces data from Lymphoseek Phase 3 study on oral and squamous cell cancers

Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.

29 Mar 2012

New treatment approach halts spread of cancer cells into normal brain tissue

Treating invasive brain tumors with a combination of chemotherapy and radiation has improved clinical outcomes, but few patients survive longer than two years after diagnosis. The effectiveness of the treatment is limited by the tumor's aggressive invasion of healthy brain tissue, which restricts chemotherapy access to the cancer cells and complicates surgical removal of the tumor.

29 Mar 2012

Researchers design new treatment approach for invasive brain tumors

Researchers from Emory and the Georgia Institute of Technology have designed a new treatment approach that appears to halt the spread of cancer cells into normal brain tissue in animal models.

29 Mar 2012

Study explores relationship between traumatic early life events and gynecological cancer

An investigation that is published in the current issue of Psychotherapy and Psychosomatics explores the relationship between early life events and gynecological cancer.

29 Mar 2012

Regulatory agencies approve plans for e-Therapeutics' ETS2101 phase I trials in cancer

e-Therapeutics plc announces that regulatory agencies in the UK and the US have approved plans for phase I trials of the Company's anti-cancer drug ETS2101 and that enrolment of patients into trials in these two countries will begin shortly.

29 Mar 2012

DSMB recommends Bionovo to continue Menerba Phase 3 trial for hot flashes

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, announced today that the Company's independent Data Safety Monitoring Board (DSMB) recommended that the Phase 3 trial of Menerba (MF101) could continue as designed after an initial review of its clinical safety and tolerability data.

29 Mar 2012

Perspectives on health law challenge: Does court recognize its own limits?; A dubious link to Civil Rights Act; The burden on young people

In ruling on the constitutionality of requiring most Americans to obtain health insurance, the Supreme Court faces a central test: whether it will recognize limits on its own authority to overturn well-founded acts of Congress.

29 Mar 2012

Galectin closes underwritten public offering of 1,333,361 units

Galectin Therapeutics Inc. today announced it has closed its underwritten public offering of 1,333,361 units (including 173,916 units that were offered and sold by Galectin pursuant to the exercise in-full of the underwriter's over-allotment option) at a price to the public of $9.00 per unit, with each unit consisting of two common voting shares, par value $0.001 per share and one warrant to purchase one share of Common Stock.

29 Mar 2012

MabCure retains CUNY CAT to evaluate monoclonal antibodies against ovarian cancer

MabCure Inc., a leading developer of antibody-based technology for the diagnosis and treatment of ovarian, prostate, colorectal and other cancers, has retained the CUNY Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.

29 Mar 2012

Cancer News and Research

Latest Cancer News and Research

Oncothyreon proposes underwritten public offering of common stock

Vaccination for HPV reduces risk of renewed disease

OncoSec Medical closes sale of 31,000,000 shares of common stock in registered public offering

New technique could restore fertility of boys undergoing cancer treatment

Obstacles standing in the way of cancer prevention

Study calls for re-examination of criteria used to prioritize liver transplant candidates

Change in registry protocols leads to underreporting of myeloid malignancies

Sun damage revealed by UV photographs show skin cancer risk

Increasing incidences of brain tumours calls for more spend on vital research

Broad Institute, Novartis develop cancer cell line encyclopedia

Roche announces increase in offer price for outstanding Illumina shares

Navidea announces data from Lymphoseek Phase 3 study on oral and squamous cell cancers

New treatment approach halts spread of cancer cells into normal brain tissue

Researchers design new treatment approach for invasive brain tumors

Study explores relationship between traumatic early life events and gynecological cancer

Regulatory agencies approve plans for e-Therapeutics' ETS2101 phase I trials in cancer

DSMB recommends Bionovo to continue Menerba Phase 3 trial for hot flashes

Perspectives on health law challenge: Does court recognize its own limits?; A dubious link to Civil Rights Act; The burden on young people

Galectin closes underwritten public offering of 1,333,361 units

MabCure retains CUNY CAT to evaluate monoclonal antibodies against ovarian cancer

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in